Corcept Therapeutics Incorporated (CORT)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	136,952	143,359	127,938	121,929	107,282	98,112	98,869	100,718	112,634	126,799	131,097	131,608	124,477	118,323	106,810	110,129	128,202	132,708	140,993	130,364
Revenue (ttm)	US$ in thousands	675,040	628,555	569,610	523,529	482,375	450,026	428,153	413,824	401,858	397,624	392,027	380,229	365,978	352,891	343,087	340,064	353,874	356,034	351,212	334,904
Operating profit margin		20.29%	22.81%	22.46%	23.29%	22.24%	21.80%	23.09%	24.34%	28.03%	31.89%	33.44%	34.61%	34.01%	33.53%	31.13%	32.38%	36.23%	37.27%	40.14%	38.93%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $136,952K ÷ $675,040K
= 20.29%

Corcept Therapeutics Incorporated's operating profit margin has exhibited fluctuating trends over the period from March 31, 2020, to December 31, 2024. The company's operating profit margin started at a relatively high level of 38.93% in March 2020 and showed a slight improvement in the following quarter, reaching 40.14% in June 2020. However, the margin began to decline gradually over the subsequent periods, dropping to 20.29% by December 31, 2024.

The downward trajectory of the operating profit margin suggests that Corcept Therapeutics Incorporated may be facing challenges in maintaining profitability relative to its operating costs. It is important for the company to closely monitor and manage its operating expenses and revenue generation in order to improve and sustain its operating profit margin in the future.

Overall, the decreasing trend in the operating profit margin indicates potential inefficiencies in the company's operations or could be reflective of competitive pressures or changes in the industry landscape that may be impacting its profitability. Continued monitoring and strategic management will be key for Corcept Therapeutics Incorporated to address these challenges and enhance its financial performance.